Analysts Offer Insights on Healthcare Companies: Gain Therapeutics (GANX) and Reviva Pharmaceuticals Holdings (RVPH)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Gain Therapeutics (GANX – Research Report) and Reviva Pharmaceuticals Holdings (RVPH – Research Report) with bullish sentiments.
Confident Investing Starts Here:
Gain Therapeutics (GANX)
BTIG analyst Thomas Shrader maintained a Buy rating on Gain Therapeutics on May 15 and set a price target of $10.00. The company's shares closed last Friday at $2.01.
According to TipRanks.com, Shrader is a 1-star analyst with an average return of -1.0% and a 33.4% success rate. Shrader covers the Healthcare sector, focusing on stocks such as Coya Therapeutics, Inc., Acumen Pharmaceuticals, and Arcturus Therapeutics.
Gain Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $8.00, which is a 337.2% upside from current levels. In a report issued on April 30, Maxim Group also maintained a Buy rating on the stock with a $5.00 price target.
Maxim Group analyst Jason McCarthy maintained a Buy rating on Reviva Pharmaceuticals Holdings yesterday and set a price target of $5.00. The company's shares closed last Friday at $0.82, close to its 52-week low of $0.60.
According to TipRanks.com, McCarthy has 0 stars on 0-5 stars ranking scale with an average return of -21.7% and a 26.4% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, SELLAS Life Sciences Group, and Actinium Pharmaceuticals.
Currently, the analyst consensus on Reviva Pharmaceuticals Holdings is a Strong Buy with an average price target of $11.25.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
a day ago
- Business Insider
Analysts' Opinions Are Mixed on These Healthcare Stocks: Quince Therapeutics (QNCX) and Moderna (MRNA)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Quince Therapeutics (QNCX – Research Report) and Moderna (MRNA – Research Report). Confident Investing Starts Here: Quince Therapeutics (QNCX) In a report issued on June 4, Jason McCarthy from Maxim Group maintained a Buy rating on Quince Therapeutics, with a price target of $6.00. The company's shares closed last Friday at $1.17. According to McCarthy 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -19.2% and a 28.3% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Reviva Pharmaceuticals Holdings, Brainstorm Cell Therapeutics, and SELLAS Life Sciences Group. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Quince Therapeutics with a $6.67 average price target. Moderna (MRNA) In a report released today, Matt Phipps from William Blair reiterated a Hold rating on Moderna. The company's shares closed last Friday at $27.46. According to Phipps is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -8.1% and a 41.7% success rate. Phipps covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma Company, Ultragenyx Pharmaceutical, and Janux Therapeutics Inc. Currently, the analyst consensus on Moderna is a Hold with an average price target of $49.29, an 88.1% upside from current levels. In a report issued on May 27, Barclays also maintained a Hold rating on the stock with a $40.00 price target.
Yahoo
a day ago
- Yahoo
Trump loyalty is now part of job application
More than six million Americans are still looking for work, according to the latest data from the U.S. Bureau of Labor Statistics. Amid ongoing economic uncertainty, the federal government remains one of the country's most active employers, with open roles for nurses, actuaries, physicists, engineers and IT professionals listed at But prospective applicants may notice something different about the application process in 2025. Alongside typical questions about experience and qualifications, some federal job forms now ask about an applicant's alignment with presidential policy priorities, raising concerns about political screening in what are supposed to be nonpartisan civil service roles. Under guidance issued by the Chief Human Capital Officers Council (CHCOC), part of a broader federal hiring overhaul, applicants may be asked to explain how they would help implement specific executive orders or initiatives. One question currently being used reads: 'How would you help advance the President's Executive Orders and policy priorities in this role? Identify one or two relevant Executive Orders or policy initiatives that are significant to you, and explain how you would help implement them if hired.' This directive is connected to an executive order President Donald Trump that emphasizes 'merit-based' hiring over previous diversity, equity, and inclusion (DEI) considerations. The administration stated that these changes are intended to root out political bias and ensure a more ideologically aligned workforce. Critics argue that these practices resemble loyalty tests, particularly as questions of commitment to the Constitution and the President's policies appeared in job applications. Earlier this year, multiple government agencies experienced layoffs of employees who were seen as insufficiently aligned with current leadership, even in traditionally apolitical roles. Historical parallels have been raised. During the McCarthy era in the 1950s, public servants and private citizens alike were pressured to prove their loyalty to the U.S. government to root out suspected communists. Accusations and investigations often targeted personal beliefs rather than actions, leading to widespread firings, blacklisting and surveillance. Civil service roles in the U.S. were originally designed to serve the Constitution and the public, not individual officeholders. Federal employees take an oath to uphold the Constitution, a foundational distinction meant to separate American governance from monarchic or authoritarian systems. Whether the latest hiring guidelines are a temporary shift or a lasting transformation of the federal workforce remains to be seen. For now, job seekers interested in federal positions may want to prepare answers not just about their skills but about their stance on presidential policy.
Business Insider
2 days ago
- Business Insider
Analysts Offer Insights on Consumer Cyclical Companies: Five Below (FIVE) and Autoliv (ALV)
Companies in the Consumer Cyclical sector have received a lot of coverage today as analysts weigh in on Five Below (FIVE – Research Report) and Autoliv (ALV – Research Report). Confident Investing Starts Here: Five Below (FIVE) Barclays analyst Seth Sigman maintained a Hold rating on Five Below on June 5 and set a price target of $120.00. The company's shares closed last Friday at $127.35. According to Sigman 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -7.0% and a 53.9% success rate. Sigman covers the NA sector, focusing on stocks such as Driven Brands Holdings, Floor & Decor Holdings, and Advance Auto Parts. Five Below has an analyst consensus of Moderate Buy, with a price target consensus of $118.63, which is a -7.0% downside from current levels. In a report issued on May 28, Citi also maintained a Hold rating on the stock with a $121.00 price target. Autoliv (ALV) Kepler Capital analyst Alexandre Raverdy maintained a Buy rating on Autoliv on June 5 and set a price target of $100.00. The company's shares closed last Friday at $105.62. According to Raverdy is ranked #5408 out of 9607 analysts. Autoliv has an analyst consensus of Strong Buy, with a price target consensus of $111.31, a 4.8% upside from current levels. In a report issued on May 28, UBS also maintained a Buy rating on the stock with a $123.00 price target.
